This post continues my paraphrase of Jonklaas et al's 2014 "Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement." Posts in this series: 2014 ATA Thyroid therapy guidelines: 1. Levothyroxine 2014 ATA Thyroid therapy guidelines: 2. Ethics2014 ATA Therapy guidelines: 3. Desiccated thyroid2014 ATA Therapy guidelines: … Continue reading 2014 ATA Therapy guidelines: 4. Using Synthetic T3
This post concludes my response to a misleading video (10). THYROID HORMONE PHARMACEUTICALS A suspicion many people have is that thyroid hormone pharmaceuticals are very different from the thyroid hormones our bodies produce. Let's look into the claim that they are "bioidentical" in structure and function. Synthetic thyroid hormone has a counter-clockwise rotated molecule (it … Continue reading Part 5: All thyroid meds are bioidentical, but individual response varies widely
Good post on "Endocrinology Network" news, summarizing of research and trends regarding T3-based thyroid medication prescriptions for hypothyroidism around the world (not mentioning Canada, though). Fuerst, M. (2019, February 14). Physician–patient interaction may influence prescribing patterns in hypothyroidism | Endocrinology Network. Retrieved February 25, 2019, from http://www.endocrinologynetwork.com/thyroid-disorders/physicianpatient-interaction-may-influence-prescribing-patterns-hypothyroidism Apparently, In the United States, in 2017, “approximately … Continue reading Endocrinology network news reviews study on T3-based therapy prescribing
In the "Dirty Money" series on Netflix, the "Drug Short" episode (1) helped me understand some of the economic forces that may have influenced T3 / Liothyronine price hikes in the UK. It makes me concerned about the future of T3 pricing in Canada too. This episode focuses on Valeant, a Canadian pharmaceutical company that … Continue reading Dirty Money “Drug Short” episode and thyroid T3 Liothyronine
Clinical trials of T3 (Liothyronine) have been barking up the wrong tree. The limitations of their research designs are now actively harming patients who need T3 medication. Prices for T3 have been rising, medical prejudice against T3 is rising, worldwide T3 shortages are occurring, and patients who truly require T3 are being harmed by denying … Continue reading Study the patients who need T3 and are harmed by its withdrawal
